Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
Sponsor: Innostellar Biotherapeutics Co.,Ltd
Summary
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
Official title: A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
Key Details
Gender
All
Age Range
50 Years - 89 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-01-24
Completion Date
2029-10
Last Updated
2026-03-06
Healthy Volunteers
No
Interventions
LX102 subretinal injection
LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
Aflibercept intravitreal injection
Commercially available Active Comparator
Locations (11)
Anhui Provincial Hospital
Hefei, Anhui, China
Zhejiang University Eye Hospital
Hangzhou, Zhejiang, China
Peking Union Medical College Hospital
Beijing, China
West China Hospital of Sichuan University
Chengdu, China
Guangzhou Aier Eye Hospital
Guangzhou, China
Zhongshan Ophthalmic Center of Sun Yat-Sen University
Guangzhou, China
Shanghai Eye and ENT Hospital
Shanghai, China
Shanghai General Hospital
Shanghai, China
Shanxi Eye Hospital
Taiyuan, China
Tianjin Medical University Eye Hospital
Tianjin, China
Xuzhou No.1 People's Hospital
Xuzhou, China